

JOIN IQVIA AT ISPOR BALTIMORE

23rd Annual International Meeting • May 19-23, 2018 • Booth 201

REIMAGINING EVIDENCE THROUGH SCIENCE, SCALE AND TECHNOLOGY TO ENABLE BETTER DECISIONS, EVERY TIME

- Explore our new, proven innovations in real-world evidence (RWE) generation using **advanced analytics and machine learning** powered by the IQVIA CORE™
- Discover the reality of compelling, credible health economics and outcomes research to **accelerate value demonstration and increase market access**
- Understand how others are benefiting from meaningful RWE with our **case studies and 4,800+ published papers**



Debating the Future of Healthcare

Peter Pitts (Moderator), Nancy Dreyer, Marni Hall, Gregory Daniel, Marc Berger (Speakers)

Symposium • Saturday, May 19
5:30-6:30pm • Room 309 (Level 300)



Network Meta-Analysis for Various Study Designs: Stepping Outside the Randomized Controlled Trials Comfort Zone into the Real World

Christopher Schmid, Ashley Pitcher, Andreas Karabis (Discussion Leaders)

Workshop W14 • Tuesday, May 22
3:45-4:45pm • Ballroom IV (Level 400)



Digital Health: Evaluating the Evidence, Identifying Gaps, Producing Better Science

Penny Mohr, Karen Schoelles, Murray Aitken, Jasmine Bihm (Discussion Leaders)

Workshop W3 • Monday, May 21
11:00am-12:00pm • Room 309 (Level 300)



When Research Questions Collide: How Much is The United States Actually Spending on Drugs?

Michael Kleinrock (Moderator), Sean Keehan, Cynthia Cox, Sara Sadownik (Panelists)

Issue Panel IP18 • Wednesday, May 23
8:30-9:30am • Ballroom I (Level 400)



Live Demos

Don't miss the live demonstrations at our booth of **HTA Accelerator**, providing instant insights into payer decision making, and **E360™**, a proven SaaS platform to drive scalable global analytics.



Reimagining evidence generation across the spectrum of healthcare



Our **presentations and 37 poster contributions** at ISPOR demonstrate how we are putting science behind new and flexible study designs to address key research questions and specific therapy area challenges, enabling better healthcare decisions globally.

MONDAY, MAY 21	Poster ID	Title	Authors
	PRM29 A29	INPATIENT COST OF ACUTE CARE FOR SEVERE BURN PATIENTS: VALIDATION OF ECONOMIC MODEL FOR ADULTS AND CHILDREN	Bilir SP, Kruger E, Kowal S, Holmes IV H, Hickerson W, Foster K, Nystrom SV, Turley DM, Sparks J, Iyer N, Quick A
	PRM38 A38	ACCESSING NEWLY IMPLEMENTED CLAIMS DATABASES IN SOUTHEAST-ASIA: ADVANCING HEALTH RESEARCH	Ng J, Kiet PH, Petcharapiruch S
	PRM52 B2	LEVERAGING CLINICAL FIELDS FROM A US EMR DATABASE TO IDENTIFY AND CHARACTERIZE LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA) IN REAL WORLD PRACTICE SETTINGS	Aguilar D, Yuan G, Wade RL, Lu J, Lichtenstein M
	PRM62 B10	REVIEW AND VALIDATION OF CARDIOVASCULAR RISK PREDICTION MODELS IN EAST ASIAN POPULATIONS	Foos V, McEwan P, Lamotte M
	PRM75 B23	CONVERSION OF HYPOGLYCEMIA UTILITY DECREMENTS FROM CATEGORICAL UNITS REFLECTING EVENT HISTORY INTO EVENT SPECIFIC DISUTILITY SCORES APPLICABLE TO DIABETES DECISION MODELS	Foos V, McEwan P
	PRM85 B33	A REVIEW OF NICE TECHNOLOGY APPRAISALS IN ONCOLOGY USING SINGLE ARM TRIALS (SAT) EVIDENCE	Alexiou D, Chatzitheofilou I, Pi Blaque A
	PRM128 C29	ANALYZING PRESCRIPTION DATA TO TARGET HARD-TO-IDENTIFY PATIENT POPULATIONS FOR CLINICAL TRIALS: A CASE STUDY IN NARCOLEPSY	Ling T, Tzellos S
	PCV89 F20	HISTORY OF LIPID LOWERING THERAPY AND CARDIOVASCULAR MEDICATION USE AMONG PATIENTS INITIATING PCSK9 INHIBITORS IN THE UNITED STATES	Wade RL, Hines DM, Rane PB, Patel J, Harrison DJ
	PMS4 G6	A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCTS) COMPARING TERIPARATIDE TO ALENDRONATE FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS	Pagada A, Mishra RK, Rai MK, Khadloya T
	PHS32 A32	INCREMENTAL HEALTHCARE RESOURCE USE AND COSTS ASSOCIATED WITH SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES FROM SOLID TUMORS	Bhowmik D, Hines DM, Karkare S, Intorcica M, Wade RL
	PHS106 C8	HEALTHCARE RESOURCES PATTERNS AND COST ANALYSIS OF PULMONARY ARTERIAL HYPERTENSION IN A TERTIARY CARE SETTING IN MEXICO CITY	Cerezo O, Guillen-López C, Rangel-Frausto S, Arana JC, Anaya P
	PDB59 F11	ASSESSING THE BENEFITS OF CO-PAY CARD USAGE AMONG DIABETIC PATIENTS IN CANADA	Guo J, Leung A, Silva C, Stewart CJ, Khan B, Mancini J
	PRS23 H24	HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH PERSISTENT ASTHMA BY ATTAINMENT OF HEALTHCARE EFFECTIVENESS AND DATA INFORMATION SET (HEDIS) MEASURES	Mosnaim G, Ariely R, Depietro M, Near A, Huang H, Batista A, Lang K
	PRS33 I10	A COST-EFFECTIVENESS ANALYSIS OF A FIRST-IN-CLASS, TRIPLE FIXED DOSE COMBINATION THERAPY AGAINST LABA/LAMA THERAPY IN MODERATE-SEVERE COPD	Gosden TB, Pitcher A, Nour N, Madoni A, Friggi E
	PCP27 K9	EVIDENCE-BASED VALUATION: A NOVEL FRAMEWORK FOR DRUG PRICING	Doyle J, Wood B
	PCP29 K11	DELPHI METHOD: A QUALITATIVE APPROACH FOR QUANTITATIVE RESULTS	Ng J
	PCP32 K14	MEASURING TREATMENT SATISFACTION WITH MEDICATION FROM PATIENTS' PERSPECTIVE: CONCEPTUAL MODELS AND A REVIEW OF MEASURES	Gemmen E, Rodriguez AM, Palmer A, Parmenter L

POSTERS

TUESDAY, MAY 22

PHP132 C35	POTENTIAL IMPACT OF CHANGES TO BASKET OF COMPARATOR COUNTRIES FROM PMPRB7 TO PMPRB12 ON CANADIAN PRODUCT LIST PRICES	McCormick J, Van Doorn-Drennan J, Minhas J, Millson B
PHP147 D4	RELATIONSHIP BETWEEN PATIENT CHARACTERISTICS AND LENGTH OF STAY FOR SEVERE BURN PATIENTS: ANALYSIS OF THE AMERICAN BURN ASSOCIATION NATIONAL BURN REPOSITORY	Kruger E, Bilir SP, Kowal S, Han E
PHP157 D13	ONLINE METHODS FOR THE ELECTRONIC VALIDATION OF THE TREATMENT SATISFACTION FOR MEDICATION QUESTIONNAIRE	Rodriguez AM, Williams P, Palmer A, Gemmen E, Parmenter L
PMH31 J3	COST-EFFECTIVENESS ANALYSIS OF AMISULPRIDE AND OLANZAPINE FOR PATIENTS WITH SCHIZOPHRENIA IN CHINA	Men P, Yi Z, Li C, Qu S, Xiong T, Yu X, Zhai S
PMH34 J6	ASSESSING THE COST-EFFECTIVENESS OF THREE-MONTHLY PALIPERIDONE PALMITATE VERSUS ITS PRIOR MONTHLY FORMULATION FOR THE MANAGEMENT OF SCHIZOPHRENIA IN THE UK SETTING	Arteaga C, Nilforooshan R, Lee J, Ming T, Bird A, van Gils CW
PMH37 J9	CHANGES IN HEALTHCARE RESOURCE USE AND COSTS ASSOCIATED WITH THE USE OF ADJUNCTIVE ATYPICAL ANTIPSYCHOTICS IN MAJOR DEPRESSIVE DISORDER	Seetasith A, Greene M, Hartry A, Burudpakdee C
PMH38 J10	REDUCTION IN HOSPITALIZATIONS AND MEDICAL COST SAVINGS ASSOCIATED WITH EARLY USE OF ADJUNCTIVE ATYPICAL ANTIPSYCHOTICS IN MAJOR DEPRESSIVE DISORDER	Seetasith A, Greene M, Hartry A, Burudpakdee C
PCN36 A33	MEDI-APEX: A RETROSPECTIVE NON-INTERVENTIONAL STUDY OF PD-L1 PREVALENCE AND CLINICAL OUTCOMES FOR NON-SMALL CELL LUNG CANCER (NSCLC) IN ASIA-PACIFIC	Klein AB, Suzuki H, Ebi N, Kim S, Li Z, Berton A, Shire N, Dalvi T, Tajar A, Lecomte C
PCN67 B14	TREATMENT PATTERNS AND ECONOMIC BURDEN OF CHINESE METASTATIC COLORECTAL CANCER PATIENTS: A RETROSPECTIVE STUDY OF ELECTRONIC MEDICAL RECORDS FROM URBAN CHINA	Shen L, Ying X, Li Q, Wang W, Zhu L, Zhao Q, Nie Y, Zhu B, Ma D, Lin X, Cai X, Fang W, Peng C, Chen Y, Fang H, Li H, Wang N, Xu R
PCN164 D17	SYMPTOMS AND IMPACTS IN ADVANCED/METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER: FINDINGS FROM QUALITATIVE PATIENT INTERVIEWS	Morlock R, Holmstrom S, Hawryluk E, Bruce R, Crooks P, Paty J
PCN172 E1	VALIDITY OF PATIENT-REPORTED OUTCOMES FROM COLUMBUS, A RANDOMIZED OPEN LABEL PHASE III CLINICAL TRIAL OF ENCORAFENIB PLUS BINMETINIB VS VEMURAFENIB IN ADVANCED BRAF-MUTANT MELANOMA	Rahhali N, Chalem Y, Niemira J, van Gils CW, Blome C, Gerlier L
PCN189 E18	HEPATOCELLULAR CARCINOMA IN THE BRAZILIAN PUBLIC HEALTH SYSTEM: A BURDEN OF ILLNESS MODEL	Ramos NB, Cruz AT, Nakada C, Campos DF, Rigolon J, Ferraz AF
PCN241 G22	REAL-WORLD TREATMENT PATTERNS FOR PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TREATED WITH IMMUNO-ONCOLOGY (IO) THERAPY	Huang H, Shenolikar R, Seal B, Tse J, Burudpakdee C
PSS3 I14	EFFICACY OF BRODALUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: A NETWORK META-ANALYSIS	Xue W, Barbeau M, Khoudigian-Sinani S, Gray E, Saharia P, Frieder D
PSS12 I23	COST-EFFECTIVENESS ANALYSIS OF BRODALUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA	Xue W, Gray E, Barbeau M, Khoudigian-Sinani S, Frieder D
PSS32 J18	ANTI-VEGF DOSING INTERVALS IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A RETROSPECTIVE COHORT STUDY IN AUSTRALIA	Skelly A, Rodriguez Torres L, Griner R, Bezlyak V, Kap EJ, Sagkriotis A
PSS33 J19	BILATERAL TREATMENT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A RETROSPECTIVE COHORT STUDY IN THE US	Skelly A, Rodriguez Torres L, Griner R, Bezlyak V, Sagkriotis A
PUK9 K5	COST-EFFECTIVENESS OF TREATING OVERACTIVE BLADDER WITH MIRABEGRON VERSUS ANTIMUSCARINICS IN MEXICO	Ng DB, Parisé H, Dea K, Espinosa R, Anaya P, Gooch K
PSY10 F19	REAL-WORLD CLINICAL EFFECTIVENESS OF LIRAGLUTIDE 3.0 MG FOR WEIGHT MANAGEMENT IN CANADA	Wharton S, Liu A, Pakseresht A, Nørtoft E, Haase CL, Mancini J, Power GS, VanderLelie S, Christensen RA
PSY72 I8	DEVELOPMENT OF A PATIENT-REPORTED OUTCOME (PRO) INSTRUMENT FOR PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA	Oladapo AO, Ito D, Hibbard C, Hare TM, Krupnick RN, Ewenstein BM

WED, MAY 23

CONTACT US

RWInfo@iqvia.com

www.iqvia.com

